Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GL… (NCT07575399) | Clinical Trial Compass
Not Yet RecruitingPhase 3
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
300 participantsStarted 2026-05-25
Plain-language summary
Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
Who can participate
Age range18 Years – 99 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Body Mass Index (BMI) ≥ 25 at screening.
* Weight loss of ≥ 10% on weekly GLP-1 RA.
* Stable body weight.
* Stable dose of GLP-1RA.
* Stable gastrointestinal (GI) tolerability.
* Contraception for females.
* Willingness to follow trial procedures for the duration of the trial.
Exclusion Criteria:
* Obesity induced by other endocrine disorders (ex: Cushing's syndrome).
* Previous or planned surgical, endoscopic or device-based treatment for obesity.
* History of malignancy.
* Type 1/Type 2 diabetes mellitus (DM).
* Family or personal history of medullary thyroid cancer.
* Previous participation in a Maridebart Cafraglutide trial.
What they're measuring
1
Percent Change from Baseline in Body Weight at Week 68